BioAtla
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell BioAtla and other ETFs, options, and stocks.About BCAB
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021.
CEOJay M. Short
CEOJay M. Short
Employees76
Employees76
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2007
Founded2007
Employees76
Employees76
BCAB Key Statistics
Market cap46.75M
Market cap46.75M
Price-Earnings ratio-0.69
Price-Earnings ratio-0.69
Dividend yield—
Dividend yield—
Average volume1.21M
Average volume1.21M
High today$0.90
High today$0.90
Low today$0.8401
Low today$0.8401
Open price$0.705
Open price$0.705
Volume266.94K
Volume266.94K
52 Week high$1.90
52 Week high$1.90
52 Week low$0.24
52 Week low$0.24
Stock Snapshot
As of today, BioAtla(BCAB) shares are valued at $0.86. The company's market cap stands at 46.75M, with a P/E ratio of -0.69.
On 2025-11-17, BioAtla(BCAB) stock traded between a low of $0.84 and a high of $0.90. Shares are currently priced at $0.86, which is +2.3% above the low and -4.5% below the high.
BioAtla(BCAB) shares are trading with a volume of 266.94K, against a daily average of 1.21M.
In the last year, BioAtla(BCAB) shares hit a 52-week high of $1.90 and a 52-week low of $0.24.
In the last year, BioAtla(BCAB) shares hit a 52-week high of $1.90 and a 52-week low of $0.24.
People also own
Based on the portfolios of people who own BCAB. This list is generated using Robinhood data, and it’s not a recommendation.